Research programme: anticancer antibodies - Astellas Pharma
Alternative Names: AGS-15 MAb; AGS-16 MAb; AGS-22 MAb; AGS-23 MAb; AGS-3 MAb; AGS-33 MAb; AGS-5 MAb; AGS-8 MAbLatest Information Update: 04 Nov 2017
At a glance
- Originator Agensys
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 30 Mar 2010 Preclinical development is ongoing in USA
- 16 Jun 2008 Pharmacodynamics data from a preclinical study presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)